unresectable HCC | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

10,880 results for “unresectable HCC”

Trials

View all 9439 →

Atezolizumab+Bevacizumab+SBRT in Unresectable HCC

20 participants · First posted Oct 27, 2021

SIRT Versus cTACE for Unresectable HCC (CHANCE2506)

108 participants · First posted Apr 3, 2025

Lenvatinib, Sintilimab Plus SIRT for Unresectable HCC

30 participants · First posted Aug 15, 2023

Drugs

View all 297 →

HCC-011

Vax-NK/HCC

Vigil HCC ( Gradalis)

Organizations

View all 21 →

HCNC

Belgium

HCG HOSPITALS

India

HCW Biologics

United States

News

View all 1123 →

TACE Plus Camrelizumab and Rivoceranib Improves PFS in Unresectable HCC

Expert Outlines Patient-Specific Approach for IO Combinations in Unresectable HCC Treatment

FDA Accepts NDA Resubmission for Rivoceranib/Camrelizumab Combo in Unresectable HCC

Page 1 of 1088